[Federal Register Volume 79, Number 110 (Monday, June 9, 2014)]
[Notices]
[Pages 32999-33000]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-13345]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical Technology Enterprise Consortium

    Notice is hereby given that, on May 9, 2014, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), the Medical Technology Enterprise 
Consortium (``MTEC'') has filed written notifications simultaneously 
with the Attorney General and the Federal Trade Commission disclosing 
(1) the identities of the parties to the venture and (2) the nature and 
objectives of the venture. The notifications were filed for the purpose 
of invoking the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Pursuant to Section 6(b) of the Act, the identities of the parties 
to the venture are: Biohealth Innovation Inc., Rockville, MD; Consortia 
to Improve Medicine (CIMIT), Boston, MA; Florida Atlantic University, 
Boca Raton, FL; Indiana University, Bloomington, IN;

[[Page 33000]]

Institute for Systems Biology, Seattle, WA; Jade Therapeutics, Inc., 
Salt Lake City, UT; Johns Hopkins Technology Transfer, Baltimore, MD; 
KAI Research Inc. (KAI), Rockville, MD; Human Effects Modeling, 
Advanced Technology Inc., L-3 Communications, San Diego, CA; Maryland 
Technology Development Corp. (TEDCO), Columbia, MD; Institute for 
Collaborative Biotechnologies, University of California, Santa Barbara, 
CA; and Center for Military Medical Research, University of Pittsburgh, 
Pittsburgh, PA.
    The general area of MTEC's planned activity is (a) to enter into a 
Section 845 Other Transactions Agreement (The OT Agreement) with U.S. 
Army Medical Research and Materiel Command (the Government) for the 
funding of certain research, development, and commercialization to be 
conducted, in partnership with the Government, the Consortium, and 
Consortium Members, to enhance the medical knowledge and life cycle 
management of the medical program and to enable the Government to 
better protect, treat, and optimize Warfighter health and performance 
across the full spectrum of operations; (b) participate in 
establishment of sound technical and programmatic performance goals 
based on the needs and requirements of the Government's Technology 
Objectives and other mission requirements, (c) create programs and 
secure funding; (d) provide a unified voice to effectively articulate 
the strategically important role that military medical technologies 
play in current and future military operations; and (e) maximize the 
utilization of the Government and member capabilities and resources to 
effectively develop critical processes, procedures, drugs, vaccines, 
and devices that can be transitioned and commercialized for both 
military and civilian use.

Patricia A. Brink,
Director of Civil Enforcement Antitrust Division.
[FR Doc. 2014-13345 Filed 6-6-14; 8:45 am]
BILLING CODE